A randomized multicenter double-blind comparison of urapidil and ketanserin in hypertensive patients after coronary artery surgery

Journal of Cardiothoracic and Vascular Anesthesia

Volumn 11, Issue 6, 1997, Pages 729-736

  Van Der Stroom, Johanna G ^a,b,c,d,e   Van Wezel, Harry B ^a,b,c,d,e   Langemeijer, Johanna J M ^a,b,c,d,e   Korsten, Henricus H M ^a,b,c,d,e   Kooyman, Jan ^a,b,c,d,e   Van Der Starre, Peter J A ^a,b,c,d,e   Kai, Jasper E ^a,b,c,d,e   Porsius, Marjolein ^a,b,c,d,e   Van Den Ende, Romana ^a,b,c,d,e   Van Zwieten, Pieter A ^a,b,c,d,e  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b ST ANTONIUS HOSPITAL   (Netherlands)

^c CATHARINA HOSPITAL   (Netherlands)

^d Zuiderzeeziekenhuis ^*  (Netherlands)

^e HOSPITAL DE WEEZENLANDEN   (Netherlands)

Author keywords

Coronary artery surgery; Hypoxic pulmonary vasoconstriction; Ketanserin; Postoperative hypertension; Urapidil

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; GLYCERYL TRINITRATE; KETANSERIN; SEROTONIN 2 ANTAGONIST; URAPIDIL;

ADULT; AGED; ARTICLE; CARDIOVASCULAR SURGERY; CLINICAL TRIAL; CORONARY ARTERY DISEASE; CORONARY ARTERY SURGERY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; HEMODYNAMIC PARAMETERS; HUMAN; HYPERTENSION; HYPOXIA; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; VASOCONSTRICTION;

EID: 12644255695     PISSN: 10530770     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1053-0770(97)90166-X     Document Type: Article

References (38)

1. Estafanous FG, Tarazi RC, Viljoen JF, et al: Systemic hypertension following myocardial revascularization. Am Heart J 85:732-738, 1973
2. Roberts AJ, Niarchos AP, Subramanian VA, et al: Systemic hypertension associated with coronary artery bypass surgery: Predisposing factors, hemodynamic characteristics, humoral profile, and treatment. J Thorac Cardiovasc Surg 74:846-859, 1977
3. Wallach R, Karp RB, Reves JG, et al: Pathogenesis of paroxysmal hypertension developing during and after coronary bypass surgery: A study of hemodynamic and humoral factors. Am J Cardiol 46:559-565, 1980
4. Engelman RM, Haag B, Lemeshow S, et al: Mechanism of plasma catecholamine increases during coronary artery bypass and valve procedures. J Thorac Cardiovasc Surg 86:608-615, 1983
5. Reves JG, Karp RB, Buttner EE, et al: Neuronal and adrenomedullary catecholamine release in response to cardiopulmonary bypass in man. Circulation 66:49-55, 1982
6. van der Starre PJA, Scheijgrond HW, Reneman RS, et al: The use of ketanserin, a 5-hydroxytryptamine receptor antagonist, for treatment of postoperative hypertension following coronary artery bypass surgery. Anesth Analg 62:63-69, 1983
7. Townsend GE, Wynands JE, Whalley DG, et al: Role of reninangiotensin system in cardiopulmonary bypass hypertension. Can Anaesth Soc J 31:160-165, 1984
8. Palmer RF, Lasseter KC: Drug therapy: Sodium nitroprusside. N Engl J Med 292:294-297, 1975
9. Cohn JN, Franciosa JA: Vasodilator therapy of cardiac failure: (first of two parts). N Engl J Med 297:27-31, 1977
10. Tinker JH, Michenfelder JD: Sodium nitroprusside: Pharmacology, toxicology and therapeutics. Anesthesiology 45:340-354, 1976
11. Vesey CJ, Cole PV: Blood cyanide and thiocyanate concentrations produced by long-term therapy with sodium nitroprusside. Br J Anaesth 57:148-155, 1985
12. van der Stroom JG, van Wezel HB, Koolen JJ, et al: Comparison of the effects of urapidil and nitroprusside on hemodynamics and myocardial function in hypertension following cardiac surgery. Blood Pressure 3:31-38, 1994 (suppl 4)
13. Mollhoff T, van Aken H, Mulier JP, et al: Effects of urapidil, ketanserin and sodium nitroprusside on venous admixture and arterial oxygenation following coronary artery bypass grafting. Br J Anaesth 64:493-497, 1990
14. Nunn JF: Measurement of the pulmonary shunt. Acta Anaesthesiol Scand Suppl 70:144-153, 1978
15. Fiolet JW, Willebrands AF, Lie Kl, et al: Determination of creatine kinase isoenzyme MB (CK-MB): Comparison of methods and clinical evaluation. Clin Chim Acta 80:23-35, 1977
16. Slogoff S, Keats AS: Does chronic treatment with calcium entry blocking drugs reduce perioperative myocardial ischemia? Anesthesiology 68:676-680, 1988
17. Gray RJ, Bateman TM, Czer LS, et al: Comparison of esmolol and nitroprusside for acute post-cardiac surgical hypertension. Am J Cardiol 59:887-891, 1987
18. Hine IP, Wood WG, Mainwaring Burton RW, et al: The adrenergic response to surgery involving cardiopulmonary bypass, as measured by plasma and urinary catecholamine concentrations. Br J Anaesth 48:355-363, 1976
19. Zaritsky AL, Horowitz M, Chernow B: Glucagon antagonism of calcium channel blocker-induced myocardial dysfunction. Crit Care Med 16:246-251, 1988
20. Cooper TJ, Clutton Brock TH, Jones SN, et al: Factors relating to the development of hypertension after cardiopulmonary bypass. Br Heart J 54:91-95, 1985
21. Bolling SF, Flaherty JT, Potter AM, et al: Propranolol-induced postoperative hypertension following coronary artery bypass grafting. J Thorac Cardiovasc Surg 87:112-119, 1984
22. Brown AM: Coronary pressor reflexes. Am J Cardiol 44:849-851, 1979
23. Reneman RS, van der Starre PJA: Serotonin and acute cardiovascular disorders. Cardiovasc Drugs Ther 4:19-25, 1990
24. van Nueten JM, Janssen PAJ, de Ridder W, et al: Interaction between 5-hydroxytryptamine and other vasoconstrictor substances in the isolated femoral artery of the rabbit: Effect of ketanserin (R41468). Eur J Pharmacol 77:281-287, 1982
25. van Nueten JM, Leysen JE, Schuurkens JAJ, et al: Ketanserin: A selective antagonist of 5-HT2 serotonergic receptors. Lancet 5:297-298, 1983
26. Fozard JR: Mechanism of the hypotensive effect of ketanserin. J Cardiovasc Pharmacol 4:829-838, 1982
27. Vandenbroucke G, Foubert L, Coddens J, et al: Use of ketanserin in the treatment of hypertension following coronary artery surgery. J Cardiothor Vasc Anesth 8:324-329, 1995
28. Koss MC: Mechanism of ketanserin-induced sympatho-inhibition. Eur J Pharmacol 194:161-166, 1991
29. van Zwieten PA, de Jonge A, Wilffert B, et al: Cardiovascular effects and interaction with adrenoceptors of urapidil. Arch Int Pharmacodyn Ther 276:180-201, 1985
30. Kolassa N, Beller KD, Sanders KH: Evidence for the interaction of urapidil with 5-HT1A receptors in the brain leading to a decrease in blood pressure. Am J Cardiol 63:36C-39C, 1989
31. Kolassa N, Beller KD, Sanders KH: Involvement of brain 5-HT1A receptors in the hypotensive response to urapidil. Am J Cardiol 64:7D-10D, 1989
32. Ramage A: The mechanism of the sympathoinhibitory action of urapidil: role of 5HT1A-receptors. Br J Pharmacol 102:998-1002, 1991
33. Fozard JR, Mir AK: Are 5-HT receptors involved in the antihypertensive effect of urapidil. Br J Pharmacol 90:24, 1987
34. Anger C, Carter JA, Prys-Roberts C: Antihypertensive mechanism of ketanserin in postoperative hypertension after cardiopulmonary bypass. Anesth Analg 67:99-106, 1988
35. van der Stroom JG, van Wezel HB, Vergroesen I, et al: Comparison of the effects of urapidil and sodium nitroprusside on haemodynamic state, myocardial metabolism and function in patients during coronary artery surgery. Br J Anaesth 76:645-651, 1996
36. Petry A, Wulf H, Baumgartel M: The influence of ketanserin or urapidil on haemodynamics, stress response and kidney function during operations for myocardial revascularisation. Anaesthesia 50:312-316, 1995
37. Castelhy PA, Lear S, Cottrell JE, et al: Intrapulmonary shunting during induced hypotension. Anesth Analg 61:231-235, 1982
38. Flaherty JT, Magee PA, Gardner TL, et al: Comparison of intravenous nitroglycerin and sodium nitroprusside for treatment of acute hypertension developing after coronary artery bypass surgery. Circulation 65:1072-1077, 1982